Treace Medical Concepts Reports First Quarter 2025 Financial Results
PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025.
Recent Highlights
- Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.
- Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in the first quarter 2025 compared to $(8.3) million in the same period in 2024.
- Expanded bunion technology portfolio through limited market releases of the Nanoplasty™ and the Percuplasty™ 3D MIS Osteotomy Systems, and the SpeedMTP™ MTP Fusion System, with additional launches expected in 2025.
- Announced positive interim clinical data for Lapiplasty, Mini Lapiplasty, and Adductoplasty procedures, at the 2025 ACFAS Annual Scientific Conference.
- Broadened global patent portfolio surpassing 100 granted patents in addition to 172 pending patent applications.
“We are pleased with the positive customer responses to our three new specialized bunion systems targeting all four classes of bunion deformities while we continue to expand our differentiated body of clinical evidence and drive adoption of our flagship Lapiplasty and Adductoplasty procedures. Our first quarter results represent solid growth versus a difficult comp and strong improvements in adjusted EBITDA,” said John T. Treace, CEO, Founder and Board Member of Treace. “Looking ahead, our expanding best in class bunion portfolio and robust innovation pipeline along with significant surgeon training momentum positions Treace for accelerating growth throughout the year and to extend our leadership position within the US bunion market.”
First Quarter 2025 Financial Results
Revenue for the first quarter of 2025 was $52.6 million, representing an increase of 3% compared to $51.1 million in the first quarter of 2024. Adjusted for one less selling day in 2025, the first quarter of 2025 increased 4.5% compared to the prior year.
Gross profit for the first quarter of 2025 was $41.9 million compared to $41.0 million in the first quarter of 2024. Gross margin was 79.7% in the first quarter of 2025, compared to 80.2% in the first quarter of 2024.
Total operating expenses were $57.5 million in the first quarter of 2025, compared to total operating expenses of $59.9 million in the first quarter of 2024.
First quarter 2025 net loss was $(15.9) million, or $(0.25) per share, compared to $(18.7) million, or $(0.30) per share, for the same period in 2024. Adjusted EBITDA was $(3.8) million in the first quarter of 2025 compared to $(8.3) million for the same period in 2024. See below for additional information and a reconciliation of non-GAAP financial information.
Treace had $98.6 million of total liquidity as of March 31, 2025, comprised of $76.1 million of cash, cash equivalents and marketable securities and $22.5 million of availability under the revolving loan facility.
2025 Financial Outlook
The Company is reaffirming full-year 2025 revenue guidance of $224 million to $230 million, representing growth of 7% to 10%, compared to full-year 2024.
The Company continues to expect breakeven Adjusted EBITDA for the full-year 2025.*
Webcast and Conference Call Details
Treace will host a conference call today, May 8, 2025, at 4:30 p.m. ET to discuss its first quarter 2025 financial results. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA. Accordingly, the Company believes this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents this non-GAAP financial measure because it believes investors, analysts and rating agencies consider it to be a useful metric in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.
There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation between GAAP and non-GAAP results is presented below.
*A reconciliation of Adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.
Forward-Looking Statements
This press release and statements made during the Company’s earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: 2025 full-year guidance; anticipated liquidity; 2025 Adjusted EBITDA breakeven guidance; expected 2025 cash burn decrease; anticipated expansion of clinical evidence; expected increase in product adoptions; continued execution of strategic initiatives; belief that it is positioned for accelerating growth throughout the year and to extend its leadership position within the US bunion market; ability to effectively respond to and mitigate the impact of challenges in the current market environment, including in response to new or increased tariffs, changes in trade policies, economic uncertainty, or increased competition and accelerating adoption of MIS osteotomy solutions; anticipated future product launches and the timing of such product launches, including the timing for full commercial availability of the Nanoplasty™ and Percuplasty™ Systems and the number and pace of new product innovations through 2025; ability to increase its procedure volumes, expand its surgeon customer base, provide a suite of technologies to address the evolving needs of bunion surgeons, and increase penetration into the bunion market; strategic investments supporting its market position and long-term outlook; ability to protect and enforce its intellectual property rights, including through its recently filed patent infringement and unfair competition suit; success in defending against securities class actions and infringement of its intellectual property by third parties, including its competitors; expected seasonality; and anticipated pace of growth in the foot and ankle market. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 27, 2025. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s results for the quarter ended March 31, 2025 are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
[email protected]
| Treace Medical Concepts, Inc. Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 52,570 | $ | 51,108 | ||||
| Cost of goods sold | 10,677 | 10,127 | ||||||
| Gross profit | 41,893 | 40,981 | ||||||
| Operating expenses | ||||||||
| Sales and marketing | 36,122 | 40,328 | ||||||
| Research and development | 5,562 | 5,259 | ||||||
| General and administrative | 15,791 | 14,362 | ||||||
| Total operating expenses | 57,475 | 59,949 | ||||||
| Loss from operations | (15,582 | ) | (18,968 | ) | ||||
| Interest income | 841 | 1,535 | ||||||
| Interest expense | (1,311 | ) | (1,317 | ) | ||||
| Other income, net | 130 | 74 | ||||||
| Other non-operating income (expense), net | (340 | ) | 292 | |||||
| Net loss | $ | (15,922 | ) | $ | (18,676 | ) | ||
| Other comprehensive income (loss) | ||||||||
| Unrealized gain (loss) on marketable securities | $ | (40 | ) | $ | (94 | ) | ||
| Comprehensive loss | $ | (15,962 | ) | $ | (18,770 | ) | ||
| Net loss per share, basic and diluted | $ | (0.25 | ) | $ | (0.30 | ) | ||
| Weighted-average shares used in computing net loss per share, basic and diluted | 62,661,447 | 61,792,788 | ||||||
| Treace Medical Concepts, Inc. Balance Sheets (in thousands, except share and per share amounts) (unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 13,372 | $ | 11,350 | ||||
| Marketable securities, short-term | 62,717 | 64,327 | ||||||
| Accounts receivable, net of allowance for credit losses of $1,441 and $1,326 as of March 31, 2025 and December 31, 2024, respectively | 31,110 | 40,803 | ||||||
| Inventories | 37,940 | 39,255 | ||||||
| Prepaid expenses and other current assets | 4,298 | 5,667 | ||||||
| Total current assets | 149,437 | 161,402 | ||||||
| Property and equipment, net | 27,129 | 25,953 | ||||||
| Intangible assets, net of accumulated amortization of $1,663 and $1,425 as of March 31, 2025 and December 31, 2024, respectively | 7,837 | 8,075 | ||||||
| Goodwill | 12,815 | 12,815 | ||||||
| Operating lease right-of-use assets | 8,241 | 8,442 | ||||||
| Other non-current assets | 387 | 407 | ||||||
| Total assets | $ | 205,846 | $ | 217,094 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 13,223 | $ | 10,522 | ||||
| Accrued liabilities | 6,008 | 7,197 | ||||||
| Accrued commissions | 6,529 | 10,121 | ||||||
| Accrued compensation | 5,190 | 6,575 | ||||||
| Other liabilities | 2,230 | 510 | ||||||
| Total current liabilities | 33,180 | 34,925 | ||||||
| Long-term debt, net | 53,380 | 53,306 | ||||||
| Operating lease liabilities, net of current portion | 13,908 | 15,934 | ||||||
| Other long-term liabilities | 37 | 37 | ||||||
| Total liabilities | 100,505 | 104,202 | ||||||
| Commitments and contingencies (Note 7) | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 0 shares issued as of March 31, 2025 and December 31, 2024 | — | — | ||||||
| Common stock, $0.001 par value, 300,000,000 shares authorized; 62,967,502 and 62,385,101 shares issued as of March 31, 2025 and December 31, 2024, respectively | 63 | 62 | ||||||
| Additional paid-in capital | 311,815 | 303,004 | ||||||
| Accumulated deficit | (205,912 | ) | (189,990 | ) | ||||
| Accumulated other comprehensive (loss) income | 57 | 97 | ||||||
| Treasury stock, at cost; 75,996 and 23,391 shares as of March 31, 2025 and December 31, 2024, respectively | (682 | ) | (281 | ) | ||||
| Total stockholders’ equity | 105,341 | 112,892 | ||||||
| Total liabilities and stockholders’ equity | $ | 205,846 | $ | 217,094 | ||||
| Treace Medical Concepts, Inc. Statements of Cash Flows (in thousands) (unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (15,922 | ) | $ | (18,676 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | ||||||||
| Depreciation and amortization expense | 2,461 | 1,909 | ||||||
| Provision for allowance for credit losses | 500 | 159 | ||||||
| Share-based compensation expense | 8,693 | 7,408 | ||||||
| Non-cash lease expense | 578 | 592 | ||||||
| Amortization of debt issuance costs | 74 | 75 | ||||||
| Amortization (accretion) of premium (discount) on marketable securities, net | (77 | ) | (335 | ) | ||||
| Other, net | 187 | 90 | ||||||
| Net changes in operating assets and liabilities, net of acquisitions | ||||||||
| Accounts receivable | 9,289 | 7,821 | ||||||
| Inventory | 1,315 | (6,615 | ) | |||||
| Prepaid expenses and other assets | 1,369 | (1,495 | ) | |||||
| Other non-current assets | (76 | ) | — | |||||
| Operating lease liabilities | (785 | ) | (657 | ) | ||||
| Accounts payable | 2,701 | 9,314 | ||||||
| Accrued liabilities | (6,166 | ) | (6,918 | ) | ||||
| Other, net | 57 | 107 | ||||||
| Net cash provided by (used in) operating activities | 4,198 | (7,221 | ) | |||||
| Cash flows from investing activities | ||||||||
| Purchases of available-for-sale marketable securities | (15,090 | ) | (28,711 | ) | ||||
| Sales and maturities of available-for-sale marketable securities | 16,739 | 36,396 | ||||||
| Purchases of property and equipment | (3,543 | ) | (3,927 | ) | ||||
| Net cash provided by (used in) investing activities | (1,894 | ) | 3,758 | |||||
| Cash flows from financing activities | ||||||||
| Proceeds from exercise of employee stock options | 119 | 52 | ||||||
| Taxes from withheld shares | (401 | ) | (237 | ) | ||||
| Net cash provided by (used in) financing activities | (282 | ) | (185 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 2,022 | (3,648 | ) | |||||
| Cash and cash equivalents at beginning of period | 11,350 | 12,982 | ||||||
| Cash and cash equivalents at end of period | $ | 13,372 | $ | 9,334 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest | $ | 1,229 | $ | 1,317 | ||||
| Noncash investing activities | ||||||||
| Unrealized (gains) losses, net on marketable securities | $ | 40 | $ | 94 | ||||
| Unsettled matured marketable security and receivable from broker | $ | — | $ | 2,100 | ||||
| Noncash financing activities | ||||||||
| Legal cost financing | $ | 45 | $ | — | ||||
| Treace Medical Concepts, Inc. Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA (in thousands) (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net loss | $ | (15,922 | ) | $ | (18,676 | ) | |
| Adjustments: | |||||||
| Interest income | (841 | ) | (1,535 | ) | |||
| Interest expense | 1,311 | 1,317 | |||||
| Taxes | — | — | |||||
| Depreciation & Amortization | 2,461 | 1,909 | |||||
| EBITDA | $ | (12,991 | ) | $ | (16,985 | ) | |
| Share-based compensation expense | 8,693 | 7,408 | |||||
| Acquisition-related costs | — | 1,317 | |||||
| Litigation costs1 | 455 | — | |||||
| Adjusted EBITDA | $ | (3,843 | ) | $ | (8,260 | ) | |
1 Litigation costs related to the lawsuit the Company filed against Stryker Corporate and its subsidiary Wright Medical Technology, Inc. on October 14, 2024.
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
